Strategies To Improve Glucose Control with Mealtime Insulin

Estimated Time
1.50 hours

Release Date
Sep 30, 2021

Expiration Date
Mar 31, 2023

Method of Participation
There are no fees for participating in or receiving credits/contact hours for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.
 
Requirements for Successful Completion
In order to receive credit, learners can participate in one or more of the Modules.  Learners will receive the applicable credits/contact hours indicated for their participation in each Module, with a maximum of 1.5 credits/contact hours for all 5 Modules. A certificate of credit will be issued only upon completing the activity evaluation form. If you have questions regarding the receipt of your certificate, please contact Nicole Dane, via email at ndane@mlicme.org.
 

For Pharmacists, MLI will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, view your participation record at the NABP website: https://nabp.pharmacy/

Course Description
This CME/NCPD/CPE activity includes five individual interactive, microlearning modules addressing care and outcomes for individuals with diabetes treated with mealtime insulin (MTI).  The modules incorporate case studies with embedded questions for an active learning experience. Learners can choose to participate in one or more of the modules to address their educational interests and needs based on their scope of practice and patient population.
 
      Module 1: Initiating MTI Therapy (0.25 credit/contact hour)  
  • Importance of MTI to maintain a more normoglycemic profile
  • Selection of appropriate patients for MTI
  • Use of CGM to assess effectiveness
      Module 2: Optimizing MTI Therapy (0.25 credit/contact hour)
  •  Improving PPG and TIR
  • Application of real-world evidence to improve control
     Module 3: Second Generation Rapid-Acting Insulin Analogs for MTI Therapy (0.5 credit/contact hour)
  • Older analogs—benefits and risks
  • Newer insulin analogs
  • Ultra-rapid lispros (approved and in phase 3 trials)
     Module 4: Improving Glucose Control with MTI in Culturally Diverse Populations (0.25 credit/contact hour)
  • Factor of cultural heritage that may affect treatment efficacy
  • Potential strategies to celebrate cultural foods and traditions while adhering to a diabetic diet and MTI therapy
     Module 5: Overcoming Barriers to MTI (0.25 credit/contact hour)
  • Approaches to engage patients in decision making
  • Anticipating and responding to patient questions and fears
  • Strategies to improve adherence and satisfaction with therapy

Speakers

Accreditation and Disclosure Information

Target Audience
This CE activity is intented for endocrinologists and primary care clinicians including NPs, PAs, residents, fellows, nurses, diabetes educators, and other allied professionals who provide care for individuals with T1D or T2D eligible for or treated with MTI.
 
Educational Objectives
After completing this CE activity, the participant should be better able to:
  • Assess recent data and best practices regarding timely and effective initiation of MTI therapy
  • Identify appropriate candidates for transitioning to MTI therapy
  • Differentiate conventional rapid acting insulins from ultra-rapid analogs
  • Devise individualized treatment strategies to optimize control postprandial glucose levels and time in range with new rapid-acting insulin analogs
  • Evaluate new and emerging data regarding the mechanism of action, pharmacokinetic/pharmacodynamic profiles, and safety and efficacy of novel rapid-acting insulin analogs
  • Plan strategies to integrate robust measures of glucose control, including real world evidence, into treatment planning
  • Develop strategies to maintain glucose control with MTI therapy while celebrating cultural foods and traditions

Accreditation Credit and Support

Physician Accreditation Statement

Logo, company nameDescription automatically generatedThe Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Endocrine Society has achieved Accreditation with Commendation.

AMA PRA Category 1 Credit™
The Endocrine Society designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

While offering CME credits noted above, this program is not intended to provide extensive training or certification in the field.

Please note that while other accrediting bodies accept AMA PRA Category 1 credit, we can only award and report this credit for MDs/DOs. For those outside of this accreditation, please complete the participation evaluation and use that certificate as proof of attendance to submit to your accrediting body.

In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc., the Endocrine Society and National Committee for Quality Assurance (NCQA).  Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Successful completion of this nursing continuing professional development activity will be awarded 1.5 contact hours and 1.5 contact hours in the area of pharmacology.
 
Continuing Pharmacy Education Contact Hours
Medical Learning Institute, Inc. (MLI) designates this continuing education activity for 1.5 contact hours (0.15 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA0007322-0000-21-009-H01-P
Type of Activity: Knowledge-based
 
Interprofessional Continuing Education Credit
LogoDescription automatically generatedThis activity was planned by and for the healthcare team, and learners will receive 1.5 Interprofessional Continuing Education (IPCE) credits for learning and change.
 
Commercial Support Statement
This activity is supported by an educational grant from Lilly.
 
Disclosure & Conflict of Interest Policy
Medical Learning Institute, Inc., is committed to providing high quality continuing education to healthcare professionals, as individuals and teams, with a protected space to learn, teach, and engage in scientific discourse free from influence from ineligible companies that may have an incentive to insert commercial bias into education.  To that end, MLI requires faculty, presenters, planners, staff, and other individuals who are in a position to control the content of this CE activity to disclose all financial relationships they have had in the past 24 months with ineligible companies as defined by the ACCME, as related to the content of this CE activity, regardless of the amount or their view of the relevance to the education. All identified COI will be thoroughly vetted and mitigated according to MLI policy. These disclosures will be provided to learners prior to the start of the CE activity. 
 
Planner/Presenter
Juan Pablo Frias, MD, National Research Institute, Los Angeles, CA
Juan Pablo Frias, MD, has a financial interest/relationship or affiliation in the form of:

Consultant and/or Advisor for 89Bio, Akero, Altimmune, Axcella Health, Becton Dickenson, Boehringer Ingelheim, Carmot Therapeutics, Echosens, Eli Lilly, Gilead, Merck, Metacrine, Novo Nordisk, Pfizer, Sanofi

Grant/Research Support from Akero, Abbvie, AstraZeneca, Boehringer Ingelheim, BMS, Eli Lilly, Intercept, Janssen, Madrigal, Merck, Metacrine, NorthSea, Novartis, Novo Nordisk, Oramed, Pfizer, Poxil, Sanofi

Speakers Bureau participant with Merck, Novo Nordisk, Sanofi

Planner/Presenter
Jennifer Hall, MS, RDN, LDN, CDCES, Nutrition Services, LLC, Little Rock, Arkansas
Jennifer Hall, MS, RDN, LDN, CDCES has no relevant financial relationship(s) with ineligible companies to disclose for this educational activity.
 
Planner/Presenter
Sheron Hanks, patient, has no relevant financial relationship(s) with ineligible companies to disclose for this educational activity.
 
Planner/Presenter
Piccola Houston, patient, has no relevant financial relationship(s) with ineligible companies to disclose for this educational activity.
 
Planner/Presenter
Dhiren Patel, PharmD, CDE, BC-ADM, BCACP, Massachusetts College of Pharmacy, Boston, MA
Dhiren Patel, PharmD, CDE, BC-ADM, BCACP, has a financial interest/relationship or affiliation in the form of:

Consultant and/or Advisor for Abbott, Amarin, Astra Zeneca, Bayer, Boehringer Ingelheim, Dexcom, Insulet, Lilly, Merck, Novo Nordisk, Sanofi, Xeris, Zealand

Speakers Bureau participant with Abbott, Amarin, Astra Zeneca, Bayer, Boehringer Ingelheim, Dexcom, Insulet, Lilly, Merck, Novo Nordisk, Sanofi, Xeris, Zealand

Planner/Presenter
Jay Shubrook, DO, FACOFP, FAAFP, Touro University California, Vallejo, CA
Jay Shubrook, DO, FACOFP, FAAFP, has a financial interest/relationship or affiliation in the form of:

Consultant and/or Advisor for Astra Zeneca, Bayer, Eli Lilly

Planner/Presenter
Katherine H Whitmire, NP-c, BC-ADM, CDCES, Southwest Medical Associates, Las Vegas, NV
Katherine H Whitmire, NP-c, BC-ADM, CDCES has no relevant financial relationships with ineligible companies to disclose for this educational activity. 
 
Planning Committee and Content/Peer Reviewers
The planners and content/peer reviewers from Medical Learning Institute, Inc, the Endocrine Society and National Committee for Quality Assurance, does not have any relevant financial relationships to disclose with ineligible companies unless listed below.
 
All of the relevant financial relationships of individuals for this activity have been mitigated.
 
Disclosure of Unlabled Use
This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
 
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
 
About this Activity
The Endocrine Society, Medical Learning Institute, Inc. and The National Committee on Quality Assurance are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions.
The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of Medical Learning Institute, Inc. or any of its partners, providers, and/or supporters.